N-Desalkylflurazepam
 | |
 | |
| Systematic (IUPAC) name | |
|---|---|
|
7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 2886-65-9 |
| PubChem | CID 4540 |
| ChemSpider | 4381 |
| ChEMBL | CHEMBL974 |
| Chemical data | |
| Formula | C15H10ClFN2O |
| Molar mass | 288.70 g/mol |
| |
| Physical data | |
| Melting point | 205 to 206 °C (401 to 403 °F) [1] |
N-Desalkylflurazepam (also known as Norflurazepam) is a benzodiazepine analog and an active metabolite of several other benzodiazepine drugs including flurazepam,[2] flutoprazepam,[3] fludiazepam,[4] midazolam,[5] quazepam,[6] and ethyl loflazepate.[7][8] It is long-acting, prone to accumulation, and binds unselectively to the various benzodiazepine receptor subtypes.[6] It has been sold as a designer drug from 2016 onward.
Synonyms
- N-1-Desalkylflurazepam
- N-Desalkyl-2-oxoquazepam
- N-Desalkylflunitrazepam
- N-Desalkylflutoprazepam
- 7-Chloroflubromazepam
- Dealkylflurazepam
- Desalkylflurazepam
- Descarbethoxyloflazepate
- Norfludiazepam
- Norflurazepam
- Norflutoprazepam
- Ro 5-3367
- TL8002277
References
- ↑ SciFinder record for CAS#2886-65-9
- ↑ Riva, Roberto; De Anna, Marco; Albani, Fiorenzo; Baruzzi, Agostino (1981). "Rapid quantitation of flurazepam and its major metabolite, N-desalkylflurazepam, in human plasma by gas—liquid chromatography with electron-capture detection". Journal of Chromatography B: Biomedical Sciences and Applications 222 (3): 491–495. doi:10.1016/S0378-4347(00)84153-5.
- ↑ Barzaghi, N; Leone, L; Monteleone, M; Tomasini, G; Perucca, E (1989). "Pharmacokinetics of flutoprazepam, a novel benzodiazepine drug, in normal subjects". European journal of drug metabolism and pharmacokinetics 14 (4): 293–8. doi:10.1007/bf03190114. PMID 2633923.
- ↑ J. Descotes, ed. (1996). Human Toxicology. p. 43.
- ↑ Vogt, Susanne; Kempf, Jürgen; Buttler, Jürgen; Auwärter, Volker; Weinmann, Wolfgang (2013). "Desalkylflurazepam found in patients' samples after high-dose midazolam treatment". Drug Testing and Analysis 5 (9–10): 745–7. doi:10.1002/dta.1484. PMID 23713025.
- 1 2 Nikaido, AM; Ellinwood Jr, EH (1987). "Comparison of the effects of quazepam and triazolam on cognitive-neuromotor performance". Psychopharmacology 92 (4): 459–64. doi:10.1007/bf00176478. PMID 2888152.
- ↑ B. B. Ba, A. Iliadis, J. P. Cano; Iliadis; Cano (1989). "Pharmacokinetic modeling of ethyl loflazepate (VictanR) and its main active metabolites". Annals of Biomedical Engineering 17 (6): 633–646. doi:10.1007/bf02367467. PMID 2574017.
- ↑ Davi, H.; Guyonnet, J.; Necciari, J.; Cautreels, W. (1985). "Determination of circulating ethyl loflazepate metabolites in the baboon by radio-high-performance liquid chromatography with injection of crude plasma samples: Comparison with solvent extraction and thin-layer chromatography". Journal of Chromatography B: Biomedical Sciences and Applications 342: 159–165. doi:10.1016/S0378-4347(00)84498-9.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Tuesday, April 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.